Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kalaris Therapeutics (KLRS) Change in Cash (2019 - 2020)

Kalaris Therapeutics (KLRS) has 2 years of Change in Cash data on record, last reported at -$19.6 million in Q4 2020.

  • For Q4 2020, Change in Cash fell 175.31% year-over-year to -$19.6 million; the TTM value through Dec 2020 reached $61.6 million, changed N/A, while the annual FY2024 figure was $27.3 million, 271.04% up from the prior year.
  • Change in Cash reached -$19.6 million in Q4 2020 per KLRS's latest filing, down from $64.0 million in the prior quarter.
  • Across five years, Change in Cash topped out at $64.0 million in Q3 2020 and bottomed at -$19.6 million in Q4 2020.